Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 20/20 | 1.00 |
| ▸ | LITAF | Q99732 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8010159 | 0.88 | TNF (0.78) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2023324 | 0.87 | TNF (1.00) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2019461 | 0.86 | TNF (1.00) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL16105968 | 0.84 | TNF (0.77) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2021076 | 0.84 | TNF (0.77) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2017835 | 0.83 | TNF (1.00) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2014492 | 0.81 | TNF (0.73) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2016948 | 0.81 | TNF (1.00) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2017360 | 0.81 | TNF (0.72) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL2021197 | 0.81 | TNF (1.00) | TNFLITAFPDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2019-11-07 | — | — | US | disclosed |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2019-11-07 | — | — | US | disclosed |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | TRANSTECH PHARMA, INC. | 2018-12-20 | — | — | US | disclosed |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180071297-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | VTV THERAPEUTICS LLC | 2018-03-15 | — | — | US | disclosed |
| US-20180071297-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | VTV THERAPEUTICS LLC | 2018-03-15 | — | — | US | disclosed |
| US-20110160234-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-7964608-B2 | Tricyclic compounds as modulators of TNF-α synthesis | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964608-B2 | Tricyclic compounds as modulators of TNF-α synthesis | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964608-B2 | Tricyclic compounds as modulators of TNF-α synthesis | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2244574-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF- SYNTHESIS AND AS PDE4 INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100190808-A1 | Tricyclic Compounds As Modulators of TNF-alpha Synthesis | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190808-A1 | Tricyclic Compounds As Modulators of TNF-alpha Synthesis | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190808-A1 | Tricyclic Compounds As Modulators of TNF-alpha Synthesis | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2009094528-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094528-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, TNF | TNF 3/4885LITAF 125/4885PDE4B 2/4885 |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | TNF 4/4885LITAF 54/4885PDE4B 2/4885 |
| US-20100190808-A1 | Tricyclic Compounds As Modulators of TNF-alpha Synthesis | TNF, PDE4A, PDE4B | TNF 1/4885LITAF 30/4885PDE4B 3/4885 |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, TNF | TNF 3/4885LITAF 125/4885PDE4B 2/4885 |
| US-20110160234-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | PDE4A, PDE4B, TNF | TNF 3/4885LITAF 56/4885PDE4B 2/4885 |
| US-20180071297-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | TNF 4/4885LITAF 54/4885PDE4B 2/4885 |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | PDE4A, TNF, PDE4B | TNF 2/4885LITAF 57/4885PDE4B 3/4885 |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | TNF 4/4885LITAF 54/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.